Background: Point-of-care (POC) Cryptococcus antigen assays may provide veterinarians with a more rapid, patient-side diagnosis when compared with traditional laboratory-based latex agglutination tests.
from the western United States, British Columbia in Canada, South America, and Australia. 4, 5 Infection is thought to follow inhalation of basidiospores into the nasal cavity or lungs after which the organism disseminates hematogenously to other organs. 6 Cryptococcosis in cats typically is characterized by the presence of upper respiratory tract signs, nodular or ulcerative cutaneous lesions, chorioretinitis, or neurologic disease arising from meningoencephalitis. 3 The majority of affected dogs have disseminated C. neoformans infections and show signs that include weight loss, lethargy, anorexia, neurologic signs, gastrointestinal or respiratory signs, and nasal or cutaneous lesions. 6 The reference standard for diagnosis of cryptococcosis is fungal culture; however, diagnosis is also commonly obtained by cytology or histopathology. These diagnostic tests frequently rely on invasive procedures for specimen collection and there is often a substantial lag time between specimen submission and the reporting of results. Use of India ink stain on cerebrospinal fluid (CSF) specimens can aid in the rapid cytologic identification of this organism by highlighting the capsule, but organisms are only identified on cytologic examination of the CSF in 60%-80% of animals with cryptococcal meningitis and 44%-52% of affected people. 5, 7, 8 Biopsy specimens of affected lesions can be obtained for histopathology, and identification is confirmed with Mayer's mucicarmine stain or immunohistochemistry. 9 The cryptococcal antigen latex agglutination system (CALAS) is a quantitative serologic test that detects Cryptococcus polysaccharide capsule antigen and has been shown to be sensitive and specific for the diagnosis of cryptococcosis in veterinary patients. 5, 10, 11 This test has been applied to both serum and CSF specimens, and is considered to be among the most accurate diagnostic assays for the diagnosis of cryptococcal infections in both humans and animals. 10, 12, 13 Trained laboratory personnel are required to perform the CALAS assay, which requires serial dilutions of patient serum or CSF, prolonged incubation periods, and experience with interpretation of results. These factors often lead to a lag time of several days before the results are reported to the practitioner.
Other rapid antigen detection assays have been developed including antigen enzyme immunoassay (EIA) and immunochromatographic lateral flow assays (LFAs). These have been validated for use in human medicine for the diagnosis and monitoring of cryptococcosis with high sensitivity (93%-100%) and specificity (93%-98%). 12, [14] [15] [16] The commercially available EIA kits are automated using spectrophotometric methods, but require specialized training and equipment to perform.
Alternatively, LFAs are rapid, requiring <15 minutes to obtain results, can be performed in a practice setting, and have had good agreement with the CALAS in humans. 13, 14, 17 Studies in people also have shown improved sensitivity of a Cryptococcus LFA (Immy, Norman, CA) when compared with the CALAS. 18 Assays may consist of a dipstick test strip or cassette with a membrane to which monoclonal antibodies to cryptococcal antigen are affixed. Antigen present in biologic specimens binds to the monoclonal antibodies and can be detected using a conjugate antibody that generates a colorimetric product.
We aimed to determine the diagnostic performance of 2 commercially available immunochromatographic LFA point-of-care (POC) assays for detection of cryptococcal antigen in dogs and cats, the CrAg LFA (Immy, Norman, OK) and the CryptoPS (Biosynex, Strasbourg, France), as compared to the serologic reference standard CALAS. The former is a nonquantitative dipstick test and the latter is a semiquantitative cassette-based immunoassay.
| MATERIALS AND METHODS

| Animals
Sera from client-owned dogs and cats were obtained both prospectively and from stored specimens if a CALAS was ordered by the attending veterinarian and the assay was performed at the diagnostic laboratory at our institution. Any animals that required additional blood samples to be collected for the study were enrolled in a protocol approved by our 
| CALAS
The CALAS was performed according to the manufacturer's protocol in a single veterinary diagnostic laboratory at our institution. The procedure included a pronase step (CALAS, IMMY, Norman, OK). Titers of ≥1:2 were considered positive.
| CrAg LFA POC assay
If sufficient serum volume was available, the CrAg LFA POC assay was given priority for additional testing after the CALAS. The CrAg LFA POC is a qualitative assay and was performed by a single individual (KR) according to the manufacturer's instructions. Briefly, 40 μL of patient serum was mixed with 1 drop of the supplied LFA diluent in a microcentrifuge tube. The tip of the CrAg LFA strip was immersed in the serum/diluent mixture and incubated at room temperature for 10 minutes, after which the result was interpreted immediately. The test was considered valid only if the positive control line appeared.
The presence of a test line indicated a positive result.
| CryptoPS POC assay
The CryptoPS POC assay was performed on any serum specimen for which adequate volume was available after the CrAg LFA POC assay had been performed. Because the CryptoPS assay required a lower volume of serum than the CrAg LFA POC assay, it was also performed on specimens that did not have adequate specimen volume for the CrAg LFA POC assay. The CryptoPS POC assay was performed by a single individual (KR) according to the instructions provided by the manufacturer. This test is a semi-quantitative assay that includes 2 test result lines (T1 and T2). The appearance of a line at T1 represents a positive result (limit of detection, 25 ng/mL of capsular antigen), and the appearance of both T1 and T2 lines represents a strong positive result. The limit of detection of capsular antigen at the T2 line is 2.5 ng/mL. Briefly, the test cassette was placed on a horizontal surface and 20 μL of serum was placed into the sample well of the cassette. Three drops of the supplied diluent then were added to the cassette sample well. The cassette was incubated for 10 minutes at room temperature, and then immediately interpreted. The test was considered valid only if a positive control line was present at 10 minutes.
| Statistical analysis
Data were analyzed using statistical software (Prism, GraphPad, San Diego, CA). Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated with a 95% CI as compared to the reference standard CALAS or cytological diagnosis.
Results were used to create receiver operator curves (ROC) and the area under the curve (AUC) was calculated for each diagnostic test.
The ROC curves were compared using the DeLong method using the pROC R package (R version 3.5.1, Vienna, Austria). Sensitivity and specificity of each test was compared using a Fisher's exact test.
| RESULTS
| Dogs and cats
One hundred two serum specimens were collected from 51 dogs and 40 cats. For the CALAS-positive animals, there were 5 serum specimens from 3 dogs, and 20 serum specimens from 11 cats. More serum specimens were tested than animals because positive specimens collected 
| CrAg LFA POC results
The CrAg LFA POC assay was performed on all 25 CALAS-positive serum specimens (Figure 2 ). Two CALAS-positive specimens tested negative with the CrAg LFA POC assay (Table 1) . One was the previ- When compared with the results of the CALAS assay, the CrAg LFA POC assay had a sensitivity 92.0% (95% CI, 75.0%-98.6%) and specificity of 93.2% (95% CI, 85.1%-97.1%). A ROC curve was constructed and had an AUC of 0.93 (95% CI, 0.86-0.99). The PPV in this population was 82.1% (95% CI, 64.4%-92.1%) and the NPV was 97.2% (95% CI, 90.3%-99.5%).
| CryptoPS POC results
The CryptoPS POC assay was performed on 10/25 CALAS-positive serum specimens (Figure 2 ). The assay was negative for 2 of the When compared with the CALAS, the sensitivity of the CryptoPS POC assay was 80.0% (95% CI, 49.0%-96.5%) and the specificity was 94.9% (95% CI, 86.0%-98.6%). An ROC curve was constructed and the AUC was 0.87 (95% CI, 0.72-0.99). In this population, the PPV was 72.7% (95% CI, 43.4%-90.3%) and NPV was 96.6% (95% CI, 88.3%-99.4%).
| Comparison of POC assays
When compared to each other, no statistically significant differences were noted in sensitivity (P = .6) or specificity (P = .9) between the 2 POC assays. Additionally, no statistically significant difference was observed between the ROC curves generated for the 2 POC assays (P = .5).
| DISCUSSION
Our study evaluated the performance of 2 POC cryptococcal antigen tests on sera collected from dogs and cats. The results of these POC assays were compared to those of the CALAS, the serologic reference standard for cryptococcosis for dogs and cats. The CALAS has been previously established as an accurate diagnostic tool in dogs and cats with a sensitivity of 95%-98% and specificity of 100% when compared to diagnosis by fungal culture or microscopic identification of Cryptococcus organisms in tissue fluids or biopsy specimens. 5, 10, 11 In this population, the CrAg LFA POC assay had a sensitivity of 92% and specificity of 93% whereas the CryptoPS POC assay had a sensitivity of 80% and specificity of 95% when compared to the CALAS results, with no significant differences in performance noted between the assays.
The CrAg LFA POC assay performance has been assessed in dogs, cats, and koalas in Australia and performance was similar to that reported here, with a sensitivity of 92% and 100% in cats and dogs, respectively and specificity of 81% and 84% in cats and dogs, respectively. 19, 20 However, the results in our study differ from those found in people, where the CrAg LFA POC assay has a sensitivity of 100% whereas the CALAS had a sensitivity 91% in the same population when diagnosis of cryptococcosis was confirmed by culture, histopathologic, or molecular diagnosis. 14 The CryptoPS POC assay has a sensitivity of 100% and specificity of 98% in people when compared to the EIA. 21 These differences may be related to the choice of reference standard or because of differences in Cryptococcus infections between people and animals. Additionally, the CALAS performance may vary regionally because performance is based on prevalence of circulating molecular types and the extent to which these molecular types shed capsular antigen into body fluids.
Our objective was to compare the results of the POC assays to the results of the CALAS, not to determine the true sensitivity and specificity of these POC assays, which would require confirmation of cryptococcosis at minimum by light microscopic identification of the fungus and ideally by fungal culture. However, doing so would require collection of CSF or tissue specimens, which is invasive and expensive. In addition, fungal culture itself is costly relative to CALAS testing (> $200 per specimen at our institution compared with $50 for CALAS testing). Financial limitations therefore can affect the application of fungal culture as a reference standard in animals. Because of the established high sensitivity and specificity of the CALAS, the results of a CALAS assay generally can be relied upon in a clinical setting. 5, 10, 11 Nevertheless, we carefully scrutinized records for confir- Aspergillus galactomannan testing. 18, 23, 24 One cat with cryptococcosis and a CALAS titer of 1:4096 had a negative CrAg LFA POC test and a positive CryptoPS POC test. Interestingly, serum from this cat collected at a previous time point when the CALAS was 1:2048 tested positive using both POC assays. The
CrAg LFA POC false-negative result may have been caused by the prozone effect, as noted in people with high antigenemia. 25 With the prozone effect, fungal antigen binds in large quantities to the colloidal gold-labeled antibody in the assay, in turn preventing it from binding to the antigen complexed with immobilized antibody, leading to a falsenegative. 26 27 Because of limited specimen volumes, titration protocols were not evaluated in our study.
The main limitation of our study was reliance on CALAS titers to categorize patients as cryptococcal antigen positive or negative, because of the need for exhaustive or invasive diagnostic tests to confirm a diagnosis of cryptococcosis using microbiologic or cytologic methods, which may have been declined by owners. In some situations, it was clear that the results of the POC tests more accurately identified animals with
Cryptococcus infections than did the CALAS. The availability of a large number of control specimens from animals with a diverse range of confirmed non-Cryptococcus diagnoses for which CALAS testing had been performed would have strengthened the study. In addition, the control animals with alternative fungal infections had infections that were endemic in our geographical region (primarily coccidioidomycosis) and specificity of these POC tests may differ in other geographical regions where other fungal infections are endemic, such as blastomycosis and histoplasmosis. Another limitation of the study was the limited availability of sufficient volumes of serum to allow both POC assays to be performed.
The small sample size of patients with cryptococcosis also was a limitation of the study and precluded meaningful statistical analysis of cats and dogs separately. Previous reports have suggested higher sensitivity in dogs (100%) as compared to cats (92%) with the CrAg LFA POC and further evaluation of this finding is warranted. 19 Some of the CALAS-positive specimens in our study were from the same animal at several time points during the course of treatment and therefore were not completely independent of each other. This may have affected the statistical analysis.
In conclusion, the POC assays in our study were technically straightforward to perform and provided rapid results, with CrAg LFAPOC sensitivity of 92% and CryptoPS sensitivity of 80% and specificity approximately 95% for both assays when compared with the CALAS. Use of these assays may result in earlier diagnosis and treatment of animals with cryptococcosis. Additional, prospective studies are recommended that include a diverse range of controls with confirmed diagnoses from different geographic regions, as well as animals being treated for cryptococcosis.
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